PA5-66881

antibody from Invitrogen Antibodies

Targeting: RBM24 dJ259A10.1, FLJ30829, RNPC6

Provider product page for PA5-66881

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Immunocytochemistry [1]
Other assay [4]

Submit

Product number: PA5-66881 - Provider product page
Provider: Invitrogen Antibodies
Product name: RBM24 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Immunogen sequence: PALIQRPFGIP AHYVYPQAFV QPGVVIPHVQ PTA Highest antigen sequence identity to the following orthologs - mouse 100%, rat 100%.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.4 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

RBM24 protein structure - PA5-66881 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 RBM24 upregulation in cancer cells is associated with a worse prognosis in patients with lung cancer. (A) Representative images showing strong, moderate and weak staining of RBM24 in lung cancer tissues and their corresponding non-cancerous lung tissues using an immunohistochemistry tissue array. Magnification, x100; scale bar, 100 mu m. (B and C) Pie charts showing the percentage of (B) lung cancer samples classed as showing strong, moderate or weak RBM24 expression and (C) the corresponding non-cancerous lung tissues. (D) Kaplan-Meier analysis of overall survival in patients with lung cancer based on the expression of RBM24 protein in lung cancer tissues; P=0.0061. RBM24, RNA binding motif protein 24; Cum, cumulative.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 miR-383 enhances the sensitivity of lung adenocarcinoma cells to cisplatin through negative regulation of RBM24. (A) Protein expression levels of RBM24 were determined by immunoblotting in A549/CDDP and parental A549 cells. (B) A549/CDDP cells were transfected with siRNA NC or RBMA24 siRNA for 48 h, and RBM24 expression as assessed using western blotting. (C) Effect of RBM24 knockdown on the viability of A549/CDDP cells after treatment with different concentrations of cisplatin for 48 h. (D) Western blotting was used to determine the expression of RBM24 in A549 cells stably overexpressing RBM24 cells; uninfected and control lentivirus-infected A549 cells served as controls. (E) Effect of stable overexpression of RBM24 on the viability of A549 cells after treatment with different concentrations of cisplatin for 48 h. (F) A549 cells were transfected with miRNA NC or miR-383 inhibitor for 48 h, and RBM24 expression was assessed using western blotting. (G) Effect of miR-383 knockdown on the viability of A549 cells after treatment with different concentrations of cisplatin for 48 h. (H) A549 cells were co-transfected with miR-383 inhibitor and either RBM24 siRNA or siRNA NC for 48 h, and RBM24 expression was assessed by western blotting. (I) Effect of miR-383 and RBM24 knockdown on the viability of A549 cells after treatment with different concentrations of cisplatin for 48 h. (J) Representative images showing detectable comet tails visualized under a fluorescence microsc

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 miR-383 inhibits RBM24-mediated NF-kappaB signaling activation. (A) Immunoblotting was used to detect the expression of NF-kappaB signaling regulatory factors and downstream target genes in A549 and A549/CDPP cells stably overexpressing miR-383 (left panel). Ratio of phosphorylated p65 and IkappaBalpha to total expression of p65 and IkappaBalpha (right panels). (B) RBM24 expression was knocked down using siRNA in A549/CDDP cells, and expression of the indicated proteins was detected by western blotting (left panel). Ratio of phosphorylated p65 and IkappaBalpha to total expression of p65 and IkappaBalpha (right panels). (C) Immunoblotting was used to detect the effect of transient overexpression of RBM24 on the expression of the indicated proteins in A549/CDDP cells following restoration of miR-383 expression (left panel). Ratio of phosphorylated p65 and IkappaBalpha to total p65 and IkappaBalpha expression (right panels). * P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 miR-383 enhances the cisplatin sensitivity of lung adenocarcinoma cells in vivo . (A) Tumor sizes of the Le-control and Le-miR-383 groups after 3 weeks of treatment with cisplatin. n=9. (B) Average rate of reduction of tumor volume in the indicated groups. * P